AssayIndex

QSC-2602-L8571

Semaglutide · 5 mg declared · Qingdao Sigma Chemical Co., Ltd. · manufactured 28 Feb 2026

CHARACTERISED
Lot code
QSC-2602-L8571
Supplier
QSC — Qingdao Sigma Chemical Co., Ltd.
Compound
Semaglutide
Compound class
Incretin analogues and co-agonists
Declared label claim
5mg
Manufacture date
28 Feb 2026
Index quarter
2026-Q1
Independent assays
3
Laboratories involved
Kestrel, Medutest, VendorInvestigate
Provenance mix
Buyer-sourced ×1 · Supplier-supplied ×2
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 3
Median purity 99.41% n=3
Spread (max − min) 1.16pp n=3
Standard deviation 0.581pp n=3
96.196.897.598.298.899.5100.2This lot (QSC-2602-L8571)This lot (QSC-2602-L8571): Q1 99.09, median 99.41, Q3 99.67, n=3n=3All SemaglutideAll Semaglutide: Q1 98.24, median 98.87, Q3 99.33, n=926outlier 96.37n=926 Purity (% area)
Figure 1. This lot's independent purity results against the whole Semaglutide record set in the index. The vertical line is the index acceptance specification for the incretin analogues and co-agonists class, 97.0 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 3

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041636QSC-2602-L8571Kestrel2026-Q199.934.49Supplier-supplied2FAIL
AX-2026-041637QSC-2602-L8571Medutest2026-Q199.414.44100.5Supplier-supplied2MARGINAL
AX-2026-041638QSC-2602-L8571VendorInvestigate2026-Q198.773.85Buyer-sourced0PASS
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
Kestrel199.9399.9315min+0.2499.69
Medutest199.4199.4125min+0.0899.33
VendorInvestigate198.7798.7732min-0.1198.88

This lot contributes 3 paired comparisons to the inter-lab analysis.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)99.9099.93divergence +0.49 pp vs batch median
Total impurities (% area)not stated0.07
Largest single impurity (% area)not stated0.04
Water (%)not stated4.49
Counter-ion (%)7.66.30
Peptide content (%w/w)88.3not determined
Endotoxin (EU/mg)0.31not determined
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
deamidated (Asn→Asp, +1 Da)3 / 30.100.03–0.64
des-His1 truncate (−137 Da)2 / 30.150.04–0.27
Met(O) sulfoxide (+16 Da)2 / 30.030.02–0.03
[D-Aib8]-diastereomer1 / 30.42
tBu-protected residual (+56 Da)1 / 30.04
des-AEEA semaglutide (−145 Da)1 / 30.16
semaglutide dimer1 / 30.11
C18 diacid mono-ester1 / 30.03
Section 7

What this rollup does not establish